SEPN
Septerna Inc · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow -6.3% ·
net new positions +11.1%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 1.41M | — | $14.95M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 1.39M | — | $14.70M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 3 | Geode Capital Management ✦ (passive) | 487.96K | +19.1% | $5.16M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 369.99K | +7.4% | $3.91M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 77.64K | +3.7% | $820,676 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 51.94K | -88.1% | $549,048 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 24.90K | +8.5% | $264,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 17.77K | New | $187,871 | 0.0% | New | 1 | SEC ↗ ×2 |
| 9 | Fidelity (FMR) ✦ | 2.48K | — | $26,266 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $187,871 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 123 holders, 45.64M shares, $1.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director, 10% owner · 746.50K sh · $31.73M
Director, 10% owner · 746.50K sh · $31.73M
10% owner · 147.06K sh · $7.39M
10% owner · 141 sh · $7,202
Officer · 25.00K sh · $1.10M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
11.8% of class · View original SEC filing ↗